Back to top
more

AngioDynamics (ANGO)

(Delayed Data from NSDQ)

$8.40 USD

8.40
310,518

-0.27 (-3.11%)

Updated Aug 6, 2025 04:00 PM ET

After-Market: $8.40 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value A Growth C Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (148 out of 246)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Here's Why You Should Retain AngioDynamics (ANGO) Stock Now

by Zacks Equity Research

AngioDynamics (ANGO) continues to benefit from strength in segments but forex remains a woe.

Zacks Equity Research

Why Is AngioDynamics (ANGO) Up 15.4% Since Last Earnings Report?

by Zacks Equity Research

AngioDynamics (ANGO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

Cardinal Health (CAH) to Post Q4 Earnings: What's in Store?

by Zacks Equity Research

Cardinal Health's (CAH) fiscal fourth-quarter results are likely to reflect solid performance in the Pharmaceutical segment. However, inflation and supply chain constraints are likely to have continued.

Zacks Equity Research

AngioDynamics (ANGO) Q4 Earnings in Line, Revenues Beat Mark

by Zacks Equity Research

AngioDynamics (ANGO) registers strong revenue growth in Med Tech and Med Device businesses, as well as in its GBUs, in fourth-quarter fiscal 2022.

Zacks Equity Research

AngioDynamics (ANGO) Q4 Earnings Match Estimates

by Zacks Equity Research

AngioDynamics (ANGO) delivered earnings and revenue surprises of 0% and 5.27%, respectively, for the quarter ended May 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Here's Why You Should Retain AngioDynamics (ANGO) Stock Now

by Zacks Equity Research

AngioDynamics (ANGO) continues to benefit from strength in segments, but forex remains a woe.

Zacks Equity Research

AngioDynamics (ANGO) Q3 Earnings Top Estimates, Revenues Lag

by Zacks Equity Research

AngioDynamics (ANGO) registers strong revenue growth in its Med Tech business as well as domestic revenues in third-quarter fiscal 2022.

Zacks Equity Research

Aspira (AWH) Reports Q4 Loss, Lags Revenue Estimates

by Zacks Equity Research

Aspira (AWH) delivered earnings and revenue surprises of 11.11% and 2.58%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

New Strong Sell Stocks for March 8th

by Zacks Equity Research

ANGO, BURL, and CABGY have been added to the Zacks Rank #5 (Strong Sell) List on March 8, 2022.

Zacks Equity Research

Stereotaxis Inc. (STXS) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Stereotaxis Inc. (STXS) delivered earnings and revenue surprises of -25% and 1.73%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

AngioDynamics (ANGO) Q2 Earnings Lag Estimates, Revenues Top

by Zacks Equity Research

AngioDynamics (ANGO) registers strong revenue growth across the majority of its GBUs, as well as in domestic and international revenues in fiscal 2022 Q2.

Zacks Equity Research

Analysts Estimate AngioDynamics (ANGO) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

AngioDynamics (ANGO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Neogen (NEOG) Q2 Earnings Miss Estimates

by Zacks Equity Research

Neogen (NEOG) delivered earnings and revenue surprises of -41.18% and 1.10%, respectively, for the quarter ended November 2021. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

HEXO (HEXO) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

HEXO (HEXO) delivered earnings and revenue surprises of 10% and 12.36%, respectively, for the quarter ended October 2021. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Here's Why You Should Hold on to Glaukos (GKOS) Stock Now

by Zacks Equity Research

Glaukos Corporation (GKOS) continues to benefit from a robust product portfolio and solid performing iStent technology.

Zacks Equity Research

OPKO Health's (OPK) Arm Declares Readiness for COVID-19 Testing

by Zacks Equity Research

OPKO Health's (OPK) BioReference Laboratories announces preparedness with respect to COVID-19 testing in the advent of the Omicron Variant.

Zacks Equity Research

Here's Why You Should Retain DENTSPLY SIRONA (XRAY) Now

by Zacks Equity Research

DENTSPLY SIRONA (XRAY) continues to gain traction from a robust product portfolio. However, forex woe persists.

Urmimala Biswas headshot

Quest Diagnostics' (DGX) COVID-19 Testing Demand Up in 3 Weeks

by Urmimala Biswas

According to Quest Diagnostics (DGX), as the nation is entering the holiday season, the importance of testing service is gaining more importance with regard to minimizing the risk of community exposure of COVID-19.

Zacks Equity Research

Cooper Companies (COO) to Post Q4 Earnings: What's in Store?

by Zacks Equity Research

Cooper Companies' (COO) fiscal fourth-quarter results are likely to reflect segmental strength.

Zacks Equity Research

What's in Store for Patterson Companies' (PDCO) Q2 Earnings?

by Zacks Equity Research

Patterson Companies' (PDCO) fiscal second-quarter results are likely to reflect improvement at Dental segment.

Zacks Equity Research

Veeva Systems (VEEV) to Post Q3 Earnings: What's in Store?

by Zacks Equity Research

Veeva Systems' (VEEV) fiscal third-quarter results are likely to reflect solid show by its segments and robust product portfolio.

Zacks Equity Research

Here's Why You Should Retain Patterson Companies (PDCO) Stock

by Zacks Equity Research

Patterson Companies (PDCO) continues to benefit from strength in Animal Health business and dental business.

Zacks Equity Research

PacBio's (PACB) Collaboration to Boost Rare Disease Diagnosis

by Zacks Equity Research

PacBio's (PACB) recent partnership with ARUP Laboratories, with regard to a study, has the potential to enhance rare disease diagnosis.

Zacks Equity Research

Cardinal Health's (CAH) Arm Unveils Supply Automation Solution

by Zacks Equity Research

Cardinal Health's (CAH) business introduces new offering for clinical labs that can enable them to focus on patient care.

Zacks Equity Research

Here's Why You Should Hold on to PerkinElmer (PKI) Stock Now

by Zacks Equity Research

PerkinElmer (PKI) continues to gain momentum from a solid product portfolio and healthy margins. However, forex woes linger.